Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors

Matteo Lambertini, Arlindo R. Ferreira, Lucia Del Mastro, Romano Danesi, Paolo Pronzato

Research output: Contribution to journalArticle

Abstract

Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. The once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfilgrastim over daily G-CSFs. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
DOIs
Publication statusAccepted/In press - Oct 22 2015

Fingerprint

Chemotherapy-Induced Febrile Neutropenia
Chemotherapy
Granulocyte Colony-Stimulating Factor
Tumors
Febrile Neutropenia
Neoplasms
Biosimilar Pharmaceuticals
Pharmacology
Expert Testimony
Cost effectiveness
Neutropenia
Health care
Cost-Benefit Analysis
Observational Studies
Toxicity
pegfilgrastim
Bone
Bone Marrow
Delivery of Health Care
Drug Therapy

Keywords

  • chemotherapy-induced febrile neutropenia
  • long-acting G-CSF
  • pegfilgrastim
  • solid tumors

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. / Lambertini, Matteo; Ferreira, Arlindo R.; Del Mastro, Lucia; Danesi, Romano; Pronzato, Paolo.

In: Expert Opinion on Biological Therapy, 22.10.2015.

Research output: Contribution to journalArticle

@article{c705d180bfec4e05abd1a0a6bea7e401,
title = "Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors",
abstract = "Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. The once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfilgrastim over daily G-CSFs. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.",
keywords = "chemotherapy-induced febrile neutropenia, long-acting G-CSF, pegfilgrastim, solid tumors",
author = "Matteo Lambertini and Ferreira, {Arlindo R.} and {Del Mastro}, Lucia and Romano Danesi and Paolo Pronzato",
year = "2015",
month = "10",
day = "22",
doi = "10.1517/14712598.2015.1101063",
language = "English",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors

AU - Lambertini, Matteo

AU - Ferreira, Arlindo R.

AU - Del Mastro, Lucia

AU - Danesi, Romano

AU - Pronzato, Paolo

PY - 2015/10/22

Y1 - 2015/10/22

N2 - Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. The once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfilgrastim over daily G-CSFs. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.

AB - Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. The once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfilgrastim over daily G-CSFs. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.

KW - chemotherapy-induced febrile neutropenia

KW - long-acting G-CSF

KW - pegfilgrastim

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84944936870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944936870&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.1101063

DO - 10.1517/14712598.2015.1101063

M3 - Article

C2 - 26488491

AN - SCOPUS:84944936870

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -